BPC-157 and TB-500 get discussed together because both show up in research on tissue repair and recovery. But they are structurally unrelated, with different origins, and the literature describes different mechanisms for each. Neither is approved for human therapeutic use. Both are sold for research purposes only.
Origins and structure
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide: a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) that research describes as derived from a protein found in human gastric juice. The "157" refers to its position in that parent sequence. The fragment itself is made in the lab and isn't known to occur on its own in the body. Early work on the sequence is generally attributed to Predrag Sikirić and colleagues. Peer-reviewed studies have looked at it mostly in rodent models, examining effects on gastric mucosa, tendon, and other connective tissue. The literature characterizes it as fairly stable across various physiological environments, though that is a description from the research, not a regulatory finding.
TB-500 is a synthetic version of a peptide fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found throughout the body and involved in actin regulation. The fragment commonly sold as TB-500 corresponds to the actin-binding region of Tβ4. It is often described as the acetylated seven-residue sequence Ac-LKKTETQ. Thymosin Beta-4 itself has been studied in formal pharmaceutical settings, including early-stage clinical work on the full-length molecule (developed as RGN-259), so the underlying biology is somewhat better characterized than BPC-157's in terms of human data. TB-500 as sold for research is the synthetic fragment, not the full protein.
Proposed mechanisms
The literature describes the two compounds as acting through different pathways. That's why some researchers treat them as complementary rather than interchangeable.
BPC-157 is described as influencing nitric oxide pathways, growth hormone receptor expression, and certain growth factors tied to angiogenesis (blood vessel formation). Rodent studies have reported effects on healing of tendons, ligaments, gut lining, and muscle tissue. The proposed mechanism centers on local tissue signaling rather than systemic modulation of any single pathway.
TB-500 / Tβ4 is mostly associated in the literature with actin regulation. Actin is a structural protein central to cell motility and tissue remodeling, and Tβ4 is described as a major monomeric (G-actin) sequestering molecule in cells. The Tβ4 fragment studied most often is described as promoting cell migration, reducing inflammation markers in some models, and supporting angiogenesis. Those pathways overlap with BPC-157's but aren't identical. Because actin is everywhere in the body, some researchers note that Thymosin Beta-4's effect on actin dynamics gives it a more systemic character.
Side-by-side summary
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Origin | Synthetic; sequence from gastric protein | Synthetic fragment of Thymosin Beta-4 |
| Length | 15 amino acids | Shorter fragment of Tβ4 (full protein: 43 amino acids; fragment often Ac-LKKTETQ) |
| Primary mechanism (reported) | Nitric oxide / growth factor signaling | Actin sequestration / cell migration |
| Human data | Mostly rodent studies; limited human data | Parent protein (Tβ4) has some early-stage human research |
| Regulatory status | Not approved for human use; on FDA 503A Category 2 bulks list (Sept 2023) | Not approved for human use; on FDA 503A Category 2 bulks list (Sept 2023) |
| Commonly studied tissue focus | Gut, tendon, ligament | Muscle, cardiac tissue, general wound healing |
The table summarizes descriptions from the scientific literature. It is not a clinical comparison or a basis for use decisions.
Regulatory status
Neither compound is approved by a drug regulator for human therapeutic use. Both are sold for research purposes only, not for human consumption.
In September 2023 the U.S. FDA placed both BPC-157 and TB-500, along with more than a dozen other peptides, into Category 2 of the 503A bulk drug substances list. These are substances that, per the agency, may present significant safety risks and are therefore restricted from compounding by pharmacies for human use. The FDA cited limited human safety data, immunogenicity for certain routes of administration, and difficulties characterizing peptide-related impurities (FDA — human drug compounding). As of early 2026, the FDA had scheduled a Pharmacy Compounding Advisory Committee meeting for July 23–24, 2026 to reconsider several of these peptides, BPC-157 and TB-500 included, for possible reclassification. Commentators caution that this is a procedural step, not approval, and that any change would still require formal rulemaking (FDA Law Blog).
Separately, BPC-157 was added to the 2022 World Anti-Doping Agency Prohibited List under section S0 (non-approved substances). It was the first substance named by example in that section, and it remains prohibited in sport (USADA).
What the research does and does not establish
Both compounds have bodies of preclinical research, mostly in rodent models, that describe tissue effects. Extrapolating from animal data to human outcomes is scientifically fraught. Effect sizes, bioavailability, and human safety profiles are not established by rodent studies alone. Neither compound has completed the clinical trial process required for regulatory approval as a therapeutic.
Independent lab testing, reported by services such as Finnrick and Janoshik, focuses on the purity and identity of the research compounds as sold, not on their biological effects. A high-purity COA confirms what is in the vial. It says nothing about efficacy or safety in use.
Sources
- PubMed / NIH — peer-reviewed studies on BPC-157 and Thymosin Beta-4: pubmed.ncbi.nlm.nih.gov
- FDA — human drug compounding and bulk drug substances: fda.gov
- FDA Law Blog — 2026 reporting on the peptide compounding review: thefdalawblog.com
- USADA — BPC-157 prohibited-substance advisory: usada.org
- Finnrick — independent purity and identity testing of research peptides, cited with attribution: finnrick.com
- Janoshik Analytical — third-party COA verification and batch testing: janoshik.com
- Bachem — pharmaceutical-grade peptide synthesis reference (Thymosin Beta-4 is a catalogued compound): bachem.com